An observational study in CHD - Congenital Heart Disease, sponsored by University Hospital, Bordeaux. Recruiting at 1 site in France. Per ClinicalTrials.gov, last updated 2025-11-28.
Sponsored by University Hospital, Bordeaux · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 73 studies in Heart Defects, Congenital with a site in France — 19 open to participants now, 22 under way, none of them phase 3. Heart Defects, Congenital · France.
Among the 73 studies in Heart Defects, Congenital with a site in France, this one is the 16th largest by planned enrollment of the 39 observational ones that give a count, is one of 10 that started in 2025, is one of 39 observational ones, reaches primary completion later than 15 of the 21 other live ones, and was the 69th registered.
992 studies on the registry are indexed under Heart Defects, Congenital; 252 are open to participants now.
Browse Heart Defects, Congenital studies →19 of the 73 studies in Heart Defects, Congenital with a site in France are open now. Recruiting first, the newest first:
University Hospital, Strasbourg, France · Sites in France
Ages 0–18
Nantes University Hospital · Sites in France
Ages 0 min–36 mo
Nantes University Hospital · Sites in France
Ages up to 6 mo
Institut National de la Santé Et de la Recherche Médicale, France · Sites in France
Ages up to 50
University Hospital, Bordeaux · Sites in France
Ages 18+ · Women only · Healthy volunteers
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 156 Heart Defects, Congenital studies recruiting now, 69 (44%) set no upper age limit and 79 (51%) stop at 75 or younger; 112 take children under 18; 25 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
73 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 10 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 300 is above the median of 119 across 440 observational studies indexed under Heart Defects, Congenital.
Median enrollment 91 across the 34 interventional studies, 300 across the 39 observational. Of the 39 that completed or were terminated, 5 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 73 have an industry lead sponsor. The 10 most frequent:
University Hospital, Bordeaux is the lead sponsor of 807 studies on the registry; 198 are open to participants now.
University Hospital, Bordeaux has 7 studies filed under Heart Defects, Congenital — fewer than ten, so there is no comparison to draw.
5 of the studies in Heart Defects, Congenital with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06823635Fondation Hôpital Saint-JosephAn International Multicenter Study on Transcatheter Device Closure of Perimembranous Ventricular Septal Defects | 2026-12-31 |
| NCT04591392atHeart MedicalSafety and Efficacy Study of reSept ASD Occluder for Treating Secundum ASD | 2027-03 |
| NCT07864129University Hospital, Strasbourg, FranceVolution of Pulmonary Artery Dimensions in Tetralogy of Fallot | 2027-04-18 |
| NCT06998290University Hospital, BordeauxFeasibility of Home Telemonitoring of Infants With Congenital Heart Disease Awaiting Surgery During the First Year of Life | 2027-06-01 |
| NCT06442592Nantes University HospitalCharacterization and Support for Neurodevelopmental Disorders Associated With Congenital Heart Defects | 2027-07-08 |
Add all 5 to your calendar (.ics) → With an account.
Among the 73 studies in Heart Defects, Congenital with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
About 13 in 1000 children are born with heart disease. Current tools poorly assess heart filling in children, limiting treatment. This study explores ultrafast ultrasound imaging to measure heart stiffness and perfusion in children with congenital heart disease.
About 13/1000 children are born with heart disease. As a result of better treatment, there is an increasing population of children surviving with congenital heart disease (CHD) as well as a growing number of children with obesity, hypertension and serious chronic diseases, such as cancer and kidney disease, who are at risk of developing heart disease. All of these diseases affect the heart muscle and one of the main mechanisms resulting in heart muscle damage is the development of scar tissue (fibrosis). Fibrosis makes the heart muscle stiffer and therefore more difficult to fill. The heart must fill properly with blood in order to function well; but it is very difficult to study the filling of the heart using current diagnostic tools. One of the main challenges in pediatric cardiology is that non-invasive diagnostic approaches used in adult patients to assess heart filling (diastolic function) have proven inadequate in children. This knowledge gap has limited therapeutic progress in this vulnerable population; and to date there is no effective therapy that improves the filling of the heart.
The aim of this study is to explore new potential of ultrasound to assess diastolic function in CHD children. Ultrafast ultrasound imaging (UFUS), consisting of ultrasound images at a very high rate, is a new ultrasound approach to assess cardiac function.
Using a Verasonics system (ultrasound open platform), we will assess the myocardial stiffness and the myocardial perfusion by UFUS.
Every patient of CHD department of any age or any sex: 300 participants including 100 general population patients and 200 patients with CHD
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Every patient of CHD department of any age or any sex:
Exclusion Criteria:
Patients with CHD
Other: Cardiac Ultrafast Ultrasound
General population patients in good general health as evidenced by medical history coming to our department for a check-up OR diagnosed with small Atrial Septal Defect or small Patent Foramen Ovale
Other: Cardiac Ultrafast Ultrasound
Ultrafast ultrasound imaging(UFUS), ultrasound images at a very high rate, using a Verasonics system (ultrasound open platform).
Myocardial stiffness
assessed with ultrasound data processed using the Verasonics system, to evaluate diastolic function
Time frame: Baseline
Myocardial perfusion
assessed with ultrasound data processed using the Verasonics system, to evaluate diastolic function
Time frame: Baseline
Echocardiographic parameters
3\. Echocardiographic parameters according to international guidelines for screening for structural or functional intra-cardiac abnormalities (Lopez et al. JASE. 2024) and assessed by conventional ultrasound and ultrafast ultrasound.
Time frame: Baseline
Started Mar 2025 (actual). Primary completion is estimated for Mar 2028, 36 months after the start.
Of 178 non-industry observational studies under Heart Defects, Congenital, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 83. This study's planned 36 months is below that.
Counting every sponsor, half of 185 studies reached it within 44 months; a quarter within 17 and three quarters within 83.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Bordeaux →